Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Operating Leases (2020 - 2025)

Crescent Biopharma (CBIO) has disclosed Operating Leases for 5 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases changed N/A to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a N/A change, with the full-year FY2025 number at $1.2 million, changed N/A from a year prior.
  • Operating Leases was $1.2 million for Q4 2025 at Crescent Biopharma, down from $1.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.7 million in Q1 2021 to a low of $66844.0 in Q4 2023.
  • A 4-year average of $847542.0 and a median of $918607.0 in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 91.9% in 2022, then surged 174.16% in 2023.
  • Crescent Biopharma's Operating Leases stood at $918607.0 in 2021, then crashed by 89.59% to $95613.0 in 2022, then crashed by 30.09% to $66844.0 in 2023, then soared by 1695.22% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Operating Leases are $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.4 million (Q2 2025).